2011). In 1978‚ Merck‚ while testing invermectin (a parasite killing drug for animals)‚ found that invermectin killed a parasite similar to the one that caused river blindness. The problem for Merck was that river blindness generally only affects people in very poor areas and there was very little chance to recoup their financial investment by selling the drug. The ethical dilemma represented by this situation is focused on what course of action Merck should take. Does Merck invest precious resources
Premium Ethics Decision making Onchocerciasis
MGT 4083-Technology Strategy Case Analysis Merck & Co.: Evaluating a Drug Licensing Opportunity Introduction: Davanrik is a new drug developed by LAB Pharmaceuticals‚ which has the potential to treat depression and obesity. Davanrik was initially developed to treat depression by stimulating the receptor in the serotonin system that promotes anti-depression. However‚ it was discovered that Davanrik also blocks the receptor that causes hunger. LAB Pharmaceuticals obtained a patent for Davanrik
Premium
Merck and River Blindness (Onchocerciasis) In understanding the decision Merck made to donate medicines‚ we need to start by understanding the motivations and core values behind the company that undertook the actions. We can get some insight into these by examining and understanding their company mission statement: The mission of Merck is to provide society with superior products and services‚ innovations‚ and solutions that improve the quality of life and satisfy customer needs-to provide employees
Premium Water Water pollution Kidney
You Decide You Decide Activity (125 points) Scenario Summary You are a CPA with an office in NearLakes City and clients consisting primarily of professionals‚ entrepreneurs‚ and small business owners. John Smith‚ Esq.‚ a practicing attorney with offices near yours‚ walks in your office and wants advice from you relating to a recent influx of cash he received as a result of winning a large jury verdict on behalf of his client in a personal injury case. His wife Jane Smith accompanies him during
Premium Taxation in the United States Tax Taxation
EXECUTIVE SUMMARY Statement of the Problem Merck & Co.‚ Inc.‚ a leading pharmaceutical company‚ faces the threat of the patents of its most popular drugs expiring in 2002. The only way to counter the loss of sales from these drugs going off patent is to develop new drugs in order to refresh the company’s portfolio. LAB Pharmaceuticals‚ a small pharmaceutical company who specializes in the treatment of neurological disorders‚ has approached Merck with the opportunity to license Davanrik‚ a new
Premium Patent Pharmacology Pharmaceutical drug
MERCK: OPEN FOR INNOVATION? Founded in 1891 as an American subsidiary of his German namesake‚ Merck was once considered the “undisputed king of the pharmaceutical industry with ground‐ breaking drugs”(The Chief Executive 2003). But for the last decade‚ Merck has gone through a period of stagnation; it began to lose exclusivity patents on blockbuster drugs and has witnessed Pfizer’s rise to top place in the industry. It seemed now that internal R&D that was once the company’s main asset would
Premium Pharmaceutical industry
As a result of worldwide withdrawal of Vioxx‚ Merck faced a serious public relations crisis in the fall of 2004. Pharmaceutical giant’s officials were forced to defend company’s actions‚ its motivation for those actions‚ and its reputation after several articles‚ negatively reflecting on Merck’s behavior handling the Vioxx case‚ had been published. As an initial response to Vioxx crisis‚ the company released “An Open Letter from Merck” and “For 100 years‚ patients first” in attempt at a positive
Premium Pharmacology Pharmaceutical drug Drug
Health Rights/Responsibility 03/15/2014 Week 2 You Decide Assignment Identification After going through the case of Margie Whitson‚ the dilemma is the fact that Margie is looking to have her pacemaker removed which will in turn would end her life. So far‚ Margie Whitson has had a rough year and has come to the decision that she wants her pacemaker deactivated because she believes it is delaying her death. Her pacemaker is the only thing keeping her heart beating at this point. But even at
Premium Ethics Morality French Revolution
Merck SWOT Analysis MGT/521 July 25‚ 2012 Merck SWOT Analysis Company Overview Merck is the 2nd largest pharmaceutical company in world offering prescription medications‚ biologics‚ vaccines‚ animal health‚ and consumer care products. It generated 48 billion dollars in revenue in 2011 and has 40‚000 employees. Research and development of proprietary medicines for global marketing is the core of the business. Recent acquisitions and transactions designed to take advantage
Premium Management Strategic management Marketing
CEO Ray Gilmartin Merck’s CEO Ray Gilmartin is a significant stakeholder in the company. Since a lot of Mercks’ products patents will be expiring in the next few years Gilmartin put a big emphasis on investing into the companies research and development of new products. Gilmartin wanted this company to really focus on coming out with new products because their bottom line was going to take a hit in the next few years once the patent on their big money products runs out. Gilmartin found it an
Premium Pharmacology Finance Management occupations